Silence Therapeutics (SLN)
(Real Time Quote from BATS)
$22.09 USD
+0.21 (0.96%)
Updated Apr 30, 2024 01:13 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLN 22.09 +0.21(0.96%)
Will SLN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SLN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLN
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
SLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?
Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?
Other News for SLN
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Silence Therapeutics Board Veteran Retires
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
Silence Therapeutics Announces Upcoming AGM